# Alan P. Venook

Source: https://onco.cc/people/alan-venook/  
OnCo record `alan-venook` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.

## Summary

Alan Venook is Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center and a long-time investigator with the Alliance for Clinical Trials in Oncology. A medical oncologist in colorectal and liver cancer, he chaired CALGB/SWOG 80405, the first-line trial of cetuximab versus bevacizumab with chemotherapy in KRAS wild-type metastatic colorectal cancer, whose analyses established primary tumour sidedness as a treatment factor. His papers report that trial in JAMA and a pooled analysis of primary tumour side in RAS wild-type disease treated with EGFR directed antibodies across six randomised trials. His work spans colorectal cancer, hepatocellular carcinoma and cooperative group trials aimed at EGFR and VEGF.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Shorenstein Associate Director for Program Development, UCSF Helen Diller Family Comprehensive Cancer Center
- Specialisms: Colorectal cancer; Liver cancer; Cooperative group trials

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Alan_Venook
- UCSF profile: https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20P.%20Venook
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Venook%20AP%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Alan%20P.%20Venook

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Alliance for Clinical Trials in Oncology](https://onco.cc/companies/alliance-oncology/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)
- journals: [Annals of Oncology](https://onco.cc/journals/annals-of-oncology/)
- key papers: [Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)](https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/), [Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405](https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/), [Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials](https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/)

---
JSON: https://onco.cc/api/v1/entities/alan-venook.json